SCHEMBL3669746

SCHEMBL3669746

O=C1Nc2cccc(Br)c2C12CCN(Cc1ccccc1)CC2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.48
POLB P06746 1/20 0.48
GAA P10253 1/20 0.48
TNKS O95271 1/20 0.47
TNKS2 Q9H2K2 1/20 0.47
OPRL1 P41146 3/20 0.46
OPRM1 P35372 2/20 0.46
OPRK1 P41145 2/20 0.46
OPRD1 P41143 1/20 0.46
ALDH1A1 P00352 2/20 0.45
MEN1 O00255 1/20 0.45
CYP2C9 P11712 1/20 0.45
TSHR P16473 1/20 0.45
CYP2C19 P33261 1/20 0.45
KMT2A Q03164 1/20 0.45
HIF1A Q16665 1/20 0.45
DRD2 P14416 2/20 0.44
CYP3A4 P08684 1/20 0.44
HSD17B10 Q99714 1/20 0.44
DRD4 P21917 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19211016 0.87 HTR1A (0.49) L3MBTL1POLBGAATNKSTNKS2
SCHEMBL19235306 0.85 TNKS (0.47) L3MBTL1POLBGAATNKSTNKS2
SCHEMBL29444501 0.85 OPRL1 (0.46) L3MBTL1POLBGAAOPRL1OPRM1
SCHEMBL19235261 0.85 ALDH1A1 (0.47) L3MBTL1POLBGAAOPRL1OPRM1
SCHEMBL19235164 0.83 SIGMAR1 (0.44) OPRL1OPRM1OPRK1OPRD1ALDH1A1
SCHEMBL19235264 0.82 ADRA1B (0.47) L3MBTL1POLBGAAOPRL1OPRM1
SCHEMBL4952229 0.82 OPRL1 (0.60) L3MBTL1POLBGAAOPRL1OPRM1
SCHEMBL20783508 0.82 DRD2 (0.49) OPRL1OPRM1OPRK1OPRD1ALDH1A1
SCHEMBL3668112 0.81 TNKS (0.50) L3MBTL1POLBGAATNKSTNKS2
SCHEMBL19235362 0.81 OPRL1 (0.44) L3MBTL1POLBGAAOPRL1OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108884096-B Spiroindolinones as DDR1 inhibitors 豪夫迈·罗氏有限公司 2022-03-22 CN disclosed
EP-3414247-B1 SPIROINDOLINONES AS DDR1 INHIBITORS HOFFMANN LA ROCHE (CH) 2021-04-21 EP disclosed
EP-3414247-B1 SPIROINDOLINONES AS DDR1 INHIBITORS HOFFMANN LA ROCHE (CH) 2021-04-21 EP disclosed
US-10618897-B2 Spiroindolinones as DDR1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2020-04-14 US disclosed
US-20190071444-A1 SPIROINDOLINONES AS DDR1 INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2019-03-07 US disclosed
US-20190071444-A1 SPIROINDOLINONES AS DDR1 INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2019-03-07 US disclosed
EP-3414247-A1 SPIROINDOLINONES AS DDR1 INHIBITORS H. Hoffnabb-La Roche Ag (CH) 2018-12-19 EP disclosed
WO-2017137334-A1 SPIROINDOLINONES AS DDR1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2017-08-17 WO disclosed
WO-2017137334-A1 SPIROINDOLINONES AS DDR1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2017-08-17 WO disclosed
US-9346805-B2 Pyrimidyl cyclopentanes as Akt protein kinase inhibitors ARRAY BIOPHARMA INC. (US) 2016-05-24 US disclosed
US-20130072500-A1 PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2013-03-21 US disclosed
EP-2240483-B1 PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2013-02-27 EP disclosed
US-8324221-B2 Pyrimidyl cyclopentanes as Akt protein kinase inhibitors ARRAY BIOPHARMA INC. (US) 2012-12-04 US disclosed
US-20110053959-A1 PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2011-03-03 US disclosed
EP-2240483-A1 PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS Array Biopharma, Inc. (US) 2010-10-20 EP disclosed
WO-2009089454-A1 PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2009-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10618897-B2 Spiroindolinones as DDR1 inhibitors DDR1, DDR2, DDRGK1 L3MBTL1 4094/4885POLB 1911/4885GAA 3807/4885
US-20110053959-A1 PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS AKT1, AKT2, PIK3CA L3MBTL1 2430/4885POLB 743/4885GAA 1375/4885
US-20190071444-A1 SPIROINDOLINONES AS DDR1 INHIBITORS DDR1, DDR2, DDRGK1 L3MBTL1 4094/4885POLB 1911/4885GAA 3807/4885
US-20130072500-A1 PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS PIK3CA, AKT1, AKT2 L3MBTL1 2433/4885POLB 917/4885GAA 1535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.